ECSP055849A - Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico - Google Patents

Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Info

Publication number
ECSP055849A
ECSP055849A EC2005005849A ECSP055849A ECSP055849A EC SP055849 A ECSP055849 A EC SP055849A EC 2005005849 A EC2005005849 A EC 2005005849A EC SP055849 A ECSP055849 A EC SP055849A EC SP055849 A ECSP055849 A EC SP055849A
Authority
EC
Ecuador
Prior art keywords
human
binding molecule
nogo
antibody
pharmaceutical use
Prior art date
Application number
EC2005005849A
Other languages
English (en)
Inventor
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schenell
Martin E Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of ECSP055849A publication Critical patent/ECSP055849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a moléculas, tales como, por ejemplo, anticuerpos monoclonales o fragmentos Fab de los mismos, los cuales son capaces de enlazarse con el polipéptido NogoA humano, o NiG humano, o NiG-D20 humano, o NogoA_623-640 humano, con una constante de disociación < 1000 nM; polinucleótidos que codifican esta molécula de enlace; un vector de expresión que comprende estos polinucleótidos; el uso de esta molécula de enlace en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de enlace; y a un método de tratamiento de enfermedades asociadas con la reparación de nervios.
EC2005005849A 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico ECSP055849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound

Publications (1)

Publication Number Publication Date
ECSP055849A true ECSP055849A (es) 2005-09-20

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005849A ECSP055849A (es) 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Country Status (25)

Country Link
US (2) US7785593B2 (es)
EP (1) EP1572745B1 (es)
JP (1) JP4504200B2 (es)
KR (1) KR101215801B1 (es)
CN (1) CN100384877C (es)
AT (1) ATE475671T1 (es)
AU (1) AU2003289998B2 (es)
BR (1) BR0317161A (es)
CA (1) CA2509068C (es)
CY (1) CY1110848T1 (es)
DE (1) DE60333585D1 (es)
DK (1) DK1572745T3 (es)
EC (1) ECSP055849A (es)
ES (1) ES2349293T3 (es)
GB (1) GB0228832D0 (es)
HK (1) HK1084676A1 (es)
IL (1) IL169018A (es)
MX (1) MXPA05006265A (es)
NO (1) NO20053304L (es)
PL (1) PL210720B1 (es)
PT (1) PT1572745E (es)
RU (1) RU2350623C2 (es)
SI (1) SI1572745T1 (es)
WO (1) WO2004052932A2 (es)
ZA (1) ZA200504522B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
AU2006265276B2 (en) * 2005-07-05 2011-10-13 Glaxo Group Limited Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3007556B1 (en) * 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
EP4048692A2 (en) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Novel anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
HU219537B (hu) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
AU774367C (en) 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ES2341842T3 (es) 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausruestung Fuer Zelt
WO2003048083A2 (en) * 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
US20110059110A1 (en) 2011-03-10
IL169018A (en) 2012-07-31
PT1572745E (pt) 2010-10-21
US7785593B2 (en) 2010-08-31
RU2005121669A (ru) 2007-01-20
PL210720B1 (pl) 2012-02-29
JP4504200B2 (ja) 2010-07-14
JP2006523087A (ja) 2006-10-12
CA2509068C (en) 2012-02-07
WO2004052932A3 (en) 2004-10-21
ATE475671T1 (de) 2010-08-15
ES2349293T3 (es) 2010-12-29
PL377506A1 (pl) 2006-02-06
BR0317161A (pt) 2005-11-01
MXPA05006265A (es) 2005-12-05
RU2350623C2 (ru) 2009-03-27
NO20053304L (no) 2005-09-07
DK1572745T3 (da) 2010-10-25
DE60333585D1 (de) 2010-09-09
NO20053304D0 (no) 2005-07-06
ZA200504522B (en) 2006-03-29
KR101215801B1 (ko) 2012-12-26
CN1747971A (zh) 2006-03-15
CN100384877C (zh) 2008-04-30
SI1572745T1 (sl) 2010-12-31
HK1084676A1 (en) 2006-08-04
US8535666B2 (en) 2013-09-17
EP1572745B1 (en) 2010-07-28
CA2509068A1 (en) 2004-06-24
GB0228832D0 (en) 2003-01-15
KR20050095768A (ko) 2005-09-30
AU2003289998B2 (en) 2008-02-14
WO2004052932A2 (en) 2004-06-24
CY1110848T1 (el) 2015-06-10
US20060183678A1 (en) 2006-08-17
EP1572745A2 (en) 2005-09-14
AU2003289998A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
ECSP055849A (es) Anticuerpo (&#34;11c7&#34;) anti-nogo a y su uso farmacéutico
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BG111652A (en) ANTITEELS AGAINST THE INSULIN RECEPTOR - SIMILAR GROWTH FACTOR I
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700136A1 (ru) Анти-cd154-антитела
ATE382053T1 (de) System zur antikörperexpression und- synthese
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
CA2256308A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2006087637A3 (en) Anti her2/neu antibody
MX2009013955A (es) Dominios de union de proteina morfogenica osea (bmp) de proteinas de la familia de proteina de molecula repulsiva de la direccion (rgm) y sus fragmentos funcionales, y su uso.
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
ATE401402T1 (de) Mit syndekan interagierende proteine und deren verwendung
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания
DK1551867T3 (da) Anvendelse af poly-alfa-2,8-sialsyre-mimetiske peptider til modulering af NCAM-funktioner
ATE338764T1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
Cai et al. Identification of a cysteine-histidine thioether bridge bond in functional units d, e and f of β</inf> c<//inf>-haemocyanin of the gastropod Helix pomatia